Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: CNBC
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 919.770
Low
950.00
Averages
1192
High
1500
Current: 919.770
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Shares Near $900, Stock Split Speculation Grows
- Stock Price Near $900: Eli Lilly's shares are hovering just below the $900 mark, reflecting market confidence in its future growth, with speculation about a stock split potentially attracting a broader investor base.
- Strong Drug Sales Growth: The company's GLP-1 drugs, Mounjaro and Zepbound, are projected to generate nearly $23 billion and $13.5 billion in revenue respectively for 2025, with year-over-year growth rates of 99% and 175%, indicating robust market demand and significant growth potential.
- Low Market Penetration: Despite strong adoption, GLP-1 drug penetration among the eligible obesity population in the U.S. remains in the mid-single digits, suggesting substantial growth opportunities for Eli Lilly's obesity portfolio, especially with the upcoming launch of oral GLP-1 therapy orforglipron.
- Optimistic Future Revenue Outlook: Eli Lilly is guiding for fiscal 2026 revenue between $80 billion and $83 billion, and while management anticipates pricing pressures on revenue growth, strong volume growth is expected to more than offset this, highlighting the broad-based and durable demand for its drugs.
See More
Novo Nordisk Launches New Version of Wegovy
- New Drug Approval: On March 19, Novo Nordisk received FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in a 72-week clinical trial, significantly outperforming the original version's 15.5%, indicating potential in the weight-loss market.
- Competitive Market Pressure: Despite the improved efficacy of HD Wegovy, it still lags behind Eli Lilly's Zepbound, which achieved a 20.2% weight loss in a similar study, maintaining competitive pressure on Novo Nordisk in the obesity treatment sector.
- Future R&D Prospects: Novo Nordisk is advancing its weight-loss drug pipeline, with potential clinical trial results for candidates like Amycretin and UBT251 expected in the next two years, which could enhance the company's competitive position in the market.
- Attractive Stock Valuation: Although facing challenges, Novo Nordisk's stock is currently trading at a forward P/E of 10.9, below the healthcare sector average of 17.1, indicating its attractiveness for long-term investors and potential for stable returns.
See More
Eli Lilly Opposes White House Drug Pricing Policy
- Opposition to Policy: Eli Lilly CEO Dave Ricks stated in a CNBC interview that the company opposes the White House's push for 'Most Favored Nations' drug pricing legislation, believing it could negatively impact the U.S. pharmaceutical industry.
- Industry Context: Lilly signed 'Most Favored Nations' agreements with the Trump administration, committing to align U.S. prescription drug prices with those of other wealthy nations, aiming to address public concerns over high drug costs.
- Policy Risk Warning: Ricks warned that the congressional process could lead to outcomes that diverge significantly from the original intent, emphasizing that current policies might stifle future drug development and the vitality of the U.S. pharmaceutical sector.
- Company Response Strategy: Lilly plans to utilize all available tools to combat unfavorable policies, with Ricks indicating that the company has clearly communicated its concerns to government and congressional leaders, demonstrating Lilly's active engagement in policy discussions.
See More
Eli Lilly Gains FDA Approval, Shares Rise
- FDA Drug Approval: Eli Lilly's once-daily GLP-1 pill Foundayo received FDA approval, leading to a 4% rise in shares, which will enhance the company's competitive edge in the obesity treatment market and drive future sales growth.
- Cybersecurity Incident Impact: Hasbro's shares fell over 4% due to a cybersecurity incident involving unauthorized network access, with the company investigating the full impact and implementing protective measures, potentially increasing operational costs in the short term.
- Tobacco Product Delay: Philip Morris International's shares dropped more than 5% after the FDA delayed authorization for nicotine pouch sales, which may hinder the company's future market expansion plans, particularly among new user demographics.
- Semiconductor Buyback Plan: Intel announced a $14.2 billion buyback of a 49% stake in its Ireland Fab 34 joint venture, resulting in a 9% increase in shares, with funding sourced from cash on hand and approximately $6.5 billion in new debt, expected to strengthen its position in the global semiconductor market.
See More
Lilly's Foundayo Receives FDA Approval for Obesity Treatment
- Clinical Trial Results: In the ATTAIN-1 clinical trial, participants taking the highest dose of Foundayo lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, demonstrating the drug's significant efficacy in weight loss, which could reshape the obesity treatment market.
- Accessibility of Medication: Foundayo will be available through LillyDirect®, with commercial insurance users paying as little as $25 per month and self-pay starting at $149, which is expected to greatly enhance treatment accessibility for obesity patients and meet the market demand for convenient treatment options.
- Cardiovascular Risk Reduction: Patients using Foundayo showed significant improvements in various cardiovascular risk markers, including waist circumference, non-HDL cholesterol, and systolic blood pressure, indicating that the drug not only aids in weight loss but may also improve overall health outcomes for patients.
- Global Market Expansion: Lilly plans to launch Foundayo in over 40 countries, reflecting its ambition in the global obesity treatment market, which is expected to generate new revenue streams for the company while addressing the diverse needs for obesity treatment across different countries.
See More
FDA Approves Eli Lilly's Weight Loss Pill Foundayo
- Clinical Trial Results: Eli Lilly's GLP-1 receptor agonist Foundayo demonstrated significant efficacy in the phase 3 ATTAIN-1 and ATTAIN-2 trials, with participants losing an average of 27.3 pounds (12.4%) over 72 weeks compared to just 2.2 pounds (0.9%) in the placebo group, indicating the drug's strong potential in weight management.
- Market Launch Plan: Eli Lilly has begun accepting prescriptions for Foundayo through its LillyDirect website, with shipping set to start on April 6, followed by widespread availability through pharmacies and telehealth providers, enhancing patient access to the medication.
- Pricing Strategy: The starting monthly price for Foundayo is $149 for cash pay customers and only $25 for those with commercial insurance, a pricing strategy designed to improve drug accessibility and differentiate it from competitor Novo Nordisk's Wegovy, which costs $149 per month.
- Stock Market Reaction: Eli Lilly's shares rose approximately 5% in Wednesday trading, reflecting a positive market response to the approval of Foundayo and demonstrating investor confidence in the company's competitive position in the weight loss drug market.
See More
Eli Lilly Shares Near $900, Stock Split Speculation Grows
- Stock Price Near $900: Eli Lilly's shares are hovering just below the $900 mark, reflecting market confidence in its future growth, with speculation about a stock split potentially attracting a broader investor base.
- Strong Drug Sales Growth: The company's GLP-1 drugs, Mounjaro and Zepbound, are projected to generate nearly $23 billion and $13.5 billion in revenue respectively for 2025, with year-over-year growth rates of 99% and 175%, indicating robust market demand and significant growth potential.
- Low Market Penetration: Despite strong adoption, GLP-1 drug penetration among the eligible obesity population in the U.S. remains in the mid-single digits, suggesting substantial growth opportunities for Eli Lilly's obesity portfolio, especially with the upcoming launch of oral GLP-1 therapy orforglipron.
- Optimistic Future Revenue Outlook: Eli Lilly is guiding for fiscal 2026 revenue between $80 billion and $83 billion, and while management anticipates pricing pressures on revenue growth, strong volume growth is expected to more than offset this, highlighting the broad-based and durable demand for its drugs.
See More
Novo Nordisk Launches New Version of Wegovy
- New Drug Approval: On March 19, Novo Nordisk received FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in a 72-week clinical trial, significantly outperforming the original version's 15.5%, indicating potential in the weight-loss market.
- Competitive Market Pressure: Despite the improved efficacy of HD Wegovy, it still lags behind Eli Lilly's Zepbound, which achieved a 20.2% weight loss in a similar study, maintaining competitive pressure on Novo Nordisk in the obesity treatment sector.
- Future R&D Prospects: Novo Nordisk is advancing its weight-loss drug pipeline, with potential clinical trial results for candidates like Amycretin and UBT251 expected in the next two years, which could enhance the company's competitive position in the market.
- Attractive Stock Valuation: Although facing challenges, Novo Nordisk's stock is currently trading at a forward P/E of 10.9, below the healthcare sector average of 17.1, indicating its attractiveness for long-term investors and potential for stable returns.
See More
Eli Lilly Opposes White House Drug Pricing Policy
- Opposition to Policy: Eli Lilly CEO Dave Ricks stated in a CNBC interview that the company opposes the White House's push for 'Most Favored Nations' drug pricing legislation, believing it could negatively impact the U.S. pharmaceutical industry.
- Industry Context: Lilly signed 'Most Favored Nations' agreements with the Trump administration, committing to align U.S. prescription drug prices with those of other wealthy nations, aiming to address public concerns over high drug costs.
- Policy Risk Warning: Ricks warned that the congressional process could lead to outcomes that diverge significantly from the original intent, emphasizing that current policies might stifle future drug development and the vitality of the U.S. pharmaceutical sector.
- Company Response Strategy: Lilly plans to utilize all available tools to combat unfavorable policies, with Ricks indicating that the company has clearly communicated its concerns to government and congressional leaders, demonstrating Lilly's active engagement in policy discussions.
See More
Eli Lilly Gains FDA Approval, Shares Rise
- FDA Drug Approval: Eli Lilly's once-daily GLP-1 pill Foundayo received FDA approval, leading to a 4% rise in shares, which will enhance the company's competitive edge in the obesity treatment market and drive future sales growth.
- Cybersecurity Incident Impact: Hasbro's shares fell over 4% due to a cybersecurity incident involving unauthorized network access, with the company investigating the full impact and implementing protective measures, potentially increasing operational costs in the short term.
- Tobacco Product Delay: Philip Morris International's shares dropped more than 5% after the FDA delayed authorization for nicotine pouch sales, which may hinder the company's future market expansion plans, particularly among new user demographics.
- Semiconductor Buyback Plan: Intel announced a $14.2 billion buyback of a 49% stake in its Ireland Fab 34 joint venture, resulting in a 9% increase in shares, with funding sourced from cash on hand and approximately $6.5 billion in new debt, expected to strengthen its position in the global semiconductor market.
See More
Lilly's Foundayo Receives FDA Approval for Obesity Treatment
- Clinical Trial Results: In the ATTAIN-1 clinical trial, participants taking the highest dose of Foundayo lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, demonstrating the drug's significant efficacy in weight loss, which could reshape the obesity treatment market.
- Accessibility of Medication: Foundayo will be available through LillyDirect®, with commercial insurance users paying as little as $25 per month and self-pay starting at $149, which is expected to greatly enhance treatment accessibility for obesity patients and meet the market demand for convenient treatment options.
- Cardiovascular Risk Reduction: Patients using Foundayo showed significant improvements in various cardiovascular risk markers, including waist circumference, non-HDL cholesterol, and systolic blood pressure, indicating that the drug not only aids in weight loss but may also improve overall health outcomes for patients.
- Global Market Expansion: Lilly plans to launch Foundayo in over 40 countries, reflecting its ambition in the global obesity treatment market, which is expected to generate new revenue streams for the company while addressing the diverse needs for obesity treatment across different countries.
See More
FDA Approves Eli Lilly's Weight Loss Pill Foundayo
- Clinical Trial Results: Eli Lilly's GLP-1 receptor agonist Foundayo demonstrated significant efficacy in the phase 3 ATTAIN-1 and ATTAIN-2 trials, with participants losing an average of 27.3 pounds (12.4%) over 72 weeks compared to just 2.2 pounds (0.9%) in the placebo group, indicating the drug's strong potential in weight management.
- Market Launch Plan: Eli Lilly has begun accepting prescriptions for Foundayo through its LillyDirect website, with shipping set to start on April 6, followed by widespread availability through pharmacies and telehealth providers, enhancing patient access to the medication.
- Pricing Strategy: The starting monthly price for Foundayo is $149 for cash pay customers and only $25 for those with commercial insurance, a pricing strategy designed to improve drug accessibility and differentiate it from competitor Novo Nordisk's Wegovy, which costs $149 per month.
- Stock Market Reaction: Eli Lilly's shares rose approximately 5% in Wednesday trading, reflecting a positive market response to the approval of Foundayo and demonstrating investor confidence in the company's competitive position in the weight loss drug market.
See More
